Literature DB >> 12824772

Ascorbate treatment attenuates the Huntington behavioral phenotype in mice.

George V Rebec1, Scott J Barton, Ann M Marseilles, Kristin Collins.   

Abstract

The R6/2 mouse line expresses exon 1 of the human gene for Huntington disease (HD) and shows behavioral symptoms as early as 6 weeks of age. In the striatum, a forebrain target of HD, these animals show a behavior-related deficit in extracellular ascorbate, the deprotonated form of vitamin C. We report here that this deficit may contribute to the HD behavioral phenotype. Regular injections of ascorbate (300 mg/kg/day, 4 days/week) beginning at symptom onset restored the behavior-related release of ascorbate in striatum and also improved behavioral responding. Compared to vehicle, ascorbate treatment significantly attenuated the neurological motor signs of HD without altering overall motor activity. Ascorbate regulation of striatal function appears key for understanding HD.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12824772     DOI: 10.1097/00001756-200307010-00015

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  34 in total

Review 1.  Energy deficit in Huntington disease: why it matters.

Authors:  Fanny Mochel; Ronald G Haller
Journal:  J Clin Invest       Date:  2011-02-01       Impact factor: 14.808

2.  Corticostriatal dysfunction and glutamate transporter 1 (GLT1) in Huntington's disease: interactions between neurons and astrocytes.

Authors:  Ana María Estrada-Sánchez; George V Rebec
Journal:  Basal Ganglia       Date:  2012-07-01

3.  Lack of mutant huntingtin in cortical efferents improves behavioral inflexibility and corticostriatal dynamics in Huntington's disease mice.

Authors:  Ana María Estrada-Sánchez; Courtney L Blake; Scott J Barton; Andrew G Howe; George V Rebec
Journal:  J Neurophysiol       Date:  2019-11-06       Impact factor: 2.714

4.  Triterpenoids CDDO-ethyl amide and CDDO-trifluoroethyl amide improve the behavioral phenotype and brain pathology in a transgenic mouse model of Huntington's disease.

Authors:  Cliona Stack; Daniel Ho; Elizabeth Wille; Noel Y Calingasan; Charlotte Williams; Karen Liby; Michael Sporn; Magali Dumont; M Flint Beal
Journal:  Free Radic Biol Med       Date:  2010-03-23       Impact factor: 7.376

Review 5.  Redox Signaling by Reactive Electrophiles and Oxidants.

Authors:  Saba Parvez; Marcus J C Long; Jesse R Poganik; Yimon Aye
Journal:  Chem Rev       Date:  2018-08-27       Impact factor: 60.622

6.  Force-plate quantification of progressive behavioral deficits in the R6/2 mouse model of Huntington's disease.

Authors:  Stephen C Fowler; Benjamin R Miller; Thomas W Gaither; Michael A Johnson; George V Rebec
Journal:  Behav Brain Res       Date:  2009-03-28       Impact factor: 3.332

7.  Up-regulation of GLT1 expression increases glutamate uptake and attenuates the Huntington's disease phenotype in the R6/2 mouse.

Authors:  B R Miller; J L Dorner; M Shou; Y Sari; S J Barton; D R Sengelaub; R T Kennedy; G V Rebec
Journal:  Neuroscience       Date:  2008-02-15       Impact factor: 3.590

8.  Altered information processing in the prefrontal cortex of Huntington's disease mouse models.

Authors:  Adam G Walker; Benjamin R Miller; Jenna N Fritsch; Scott J Barton; George V Rebec
Journal:  J Neurosci       Date:  2008-09-03       Impact factor: 6.167

9.  Corticostriatal dysfunction underlies diminished striatal ascorbate release in the R6/2 mouse model of Huntington's disease.

Authors:  Jenelle L Dorner; Benjamin R Miller; Emma L Klein; Alexander Murphy-Nakhnikian; Rachel L Andrews; Scott J Barton; George V Rebec
Journal:  Brain Res       Date:  2009-07-16       Impact factor: 3.252

10.  Early exposure to dynamic environments alters patterns of motor exploration throughout the lifespan.

Authors:  S Lee Hong; Ana María Estrada-Sánchez; Scott J Barton; George V Rebec
Journal:  Behav Brain Res       Date:  2016-01-08       Impact factor: 3.332

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.